Leaving cancer behind, Agios preps submission after latest readout in rare anemia

With its oncology business in the rear view mirror, Agios is readying its first non-cancer candidate for a regulatory submission with more data in a rare anemia.

After the bell Tuesday, Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said mitapivat met the primary endpoint in a second Phase III trial, ACTIVATE-T, to treat pyruvate kinase deficiency in patients who are regularly transfused...